A PHASE 3B/4,MULTI-CENTER, DOUBLE-BLIND, RANDOMIZED, PARALLEL GROUP STUDY OF TOFACITINIB (CP-690,550) IN SUBJECTS WITH ULCERATIVE COLITIS IN STABLE REMISSION
Phase of Trial: Phase III/IV
Latest Information Update: 18 Feb 2019
At a glance
- Drugs Tofacitinib (Primary)
- Indications Ulcerative colitis
- Focus Therapeutic Use
- Acronyms RIVETING STUDY
- Sponsors Pfizer
- 30 Nov 2018 Planned End Date changed from 14 Dec 2019 to 22 Nov 2022.
- 30 Nov 2018 Planned primary completion date changed from 10 Nov 2018 to 31 Oct 2019.
- 31 Aug 2018 Biomarkers information updated